A year of cultivating connections

Expanding CARB-X

CARB-X is a non-profit public-private partnership, founded by BARDA and Wellcome Trust, dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

With the addition of the Bill and Melinda Gates Foundation and the UK Ministry of Health, CARB-X became the world’s largest transnational public-private partnership focused on developing new drugs and diagnostics to combat antibiotic resistance.

Building More Innovative Partnerships

BARDA forged a new partnership with Opiant Pharmaceuticals to develop a fast acting, longer lasting drug to address the ongoing opioid crisis and protect Americans from 21st century health security threats.

BARDA has also entered into a first-of-its-kind partnership with the Department of Defense and Spero Therapeutics to develop an oral antibiotic to treat drug-resistant infections and biothreats.

Engaging More Stakeholders

ASPR reached out in new ways to stakeholders, sponsoring listening sessions; medical countermeasures outreach sessions; a sepsis summit; a National Disaster Medical System training summit; BARDA Industry Day; congressional briefings and tours; and through the Ministerial Meeting of the Global Health Security Initiative.

Participants at NDMS Summit raise hands

ASPR Year in Review: 2017-2018

This page last reviewed: July 21, 2020